Dardennes, R <br/><br/>
Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approach.  [electronic resource] 

 -  European psychiatry : the journal of the Association of European Psychiatrists  Jun 1999 
 - 152-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0924-9338 
<br/><br/><label>Standard No.: </label>10.1016/s0924-9338(99)80734-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic Antagonists--economics<br/>Adult<br/>Antidepressive Agents, Tricyclic--economics<br/>Cost-Benefit Analysis<br/>Cyclopropanes--economics<br/>Depressive Disorder, Major--drug therapy<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Tolerance--physiology<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Milnacipran<br/>Models, Econometric<br/>Sensitivity and Specificity<br/>Selective Serotonin Reuptake Inhibitors--economics